NOVIOSENSE
NovioSense BV is a clinical-stage Dutch medical device company developing a non-invasive tear glucose sensor that sits in the lower eyelid, using enzymatic biosensing and NFC wireless communication to provide continuous glucose monitoring for Type 1 and Type 2 diabetic patients as a replacement for finger-prick testing.
- Company typePrivate
- Founded2012
- HeadquartersNijmegen, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NOVIOSENSE does
NovioSense BV is a clinical-stage medical device company founded in 2012 and headquartered at the NovioTech Campus in Nijmegen, Netherlands. The company is developing a non-invasive tear glucose sensor designed to replace the conventional finger-prick blood glucose test for diabetic patients. The device is a flexible spring-like insert (less than 2 cm in length, 1.5 mm in diameter) placed in the inferior conjunctival fornix of the lower eyelid, where it continuously measures glucose in basal tear fluid via an enzymatic glucose oxidase reaction, producing an electrical current that is read out through NFC wireless communication to a smartphone or dedicated reader.
The underlying technology integrates proprietary components: a soft polysaccharide-based hydrogel coating for comfortable extended wear, low-power ASIC chips co-developed with Fraunhofer IMS, and a European Patent for the core biosensor. Clinical development reached Technology Readiness Level 6-7, with Phase 2 results (October 2018) in six Type 1 diabetic patients demonstrating consensus error grid-validated correlation between tear and blood glucose, and a follow-on 24-patient validation study in progress. The platform has been extended beyond diabetes into sports injury prevention sensors via a 2017 NWO Perspectief partnership with TUDelft and Adidas.
The business model is pre-commercial hardware sales to healthcare providers (diabetes clinics and endocrinologists) for prescription to Type 1 and Type 2 diabetic patients, with a complementary direct-to-patient channel via NFC-enabled smartphones. Revenue has not been disclosed; the company is venture-backed (four seed rounds 2012-2016, plus Health Innovations, PPM Oost, NovioTech BV, Fraunhofer-Gesellschaft, Fraunhofer Venture, and Topfonds Gelderland as investors) and supplemented by non-dilutive European grants including a €3M Horizon 2020 Marie Curie award, a €6M NWO Perspectief program, and a €1.6M InterReg subsidy. Market introduction was targeted for Q1 2020 subject to regulatory approval, with the company continuing to seek strategic partners and risk capital to accelerate clinical validation and commercial launch.
NOVIOSENSE firmographics
Firmographics- Name
- NOVIOSENSE
- Legal name
- NovioSense BV
- Website
- https://noviosense.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NovioSense BV is a clinical-stage Dutch medical device company developing a non-invasive tear glucose sensor that sits in the lower eyelid, using enzymatic biosensing and NFC wireless communication to provide continuous glucose monitoring for Type 1 and Type 2 diabetic patients as a replacement for finger-prick testing.
- Ownership category
- akta.pro rank
NOVIOSENSE industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
- akta.pro secondary industries
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)
Keywords
Where NOVIOSENSE is headquartered
LocationHeadquarters
- HQ city
- Nijmegen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
NOVIOSENSE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Tear Glucose Sensor Device Sales: NovioSense will generate revenue through sale of non-invasive glucose monitoring devices for Type 1 and Type 2 diabetic patients. The device will be compatible with NFC-enabled smartphones as dedicated reader system.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
NOVIOSENSE product offering
Product offeringCore offering
NovioSense develops a non-invasive tear glucose sensor: a small flexible spring-like device (less than 2 cm long, 1.5 mm diameter) coated with soft hydrogel that sits in the lower eyelid to continuously measure glucose levels in tear fluid. The device uses glucose-oxidase enzymatic detection and wireless NFC communication to enable pain-free glucose monitoring for Type 1 and Type 2 diabetic patients, transmitting readings to NFC-enabled smartphones or a dedicated reader system.
Product overview
NovioSense is a single-product medical device company offering the NovioSense Glucose Sensor—a non-invasive tear glucose monitoring device designed to replace the traditional finger prick for diabetics. The core product is a flexible spring-like sensor worn under the lower eyelid that continuously measures glucose levels in tear fluid using enzymatic detection, with data readout via NFC-enabled smartphones or a dedicated reader system. The device is coated with a proprietary soft hydrogel layer for comfort during extended wear (targeting at least 2 weeks per sensor).
Differentiator
Problem solved
Functional benefit
Products and services
- NovioSense Glucose Sensor A non-invasive tear glucose sensor: a small, flexible, spring-like device (less than 2 cm long, 1.5 mm in diameter) coated with a soft hydrogel layer that sits in the lower eyelid (inferior conjunctival fornix) to continuously measure glucose in tear fluid. It uses glucose-oxidase enzymatic detection, is wirelessly powered, and transmits data via NFC to a smartphone or dedicated reader, providing pain-free continuous and on-demand glucose monitoring for Type 1 (primary) and Type 2 (secondary) diabetic patients.
Quantifiable outcome
- Phase 2 clinical trial demonstrated clinically relevant accuracy correlation between tear glucose and blood glucose in Type 1 diabetic patients
- +2 more outcomes
Companies that use NOVIOSENSE
Customer profileSegments2 records
Ideal customer profiles2 records
NOVIOSENSE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
NOVIOSENSE partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major and core.
- TUDelft (Delft University of Technology)majorLead partner in NWO Perspectief PLatform program developing sensors to prevent sports injuries. TUDelft received €4M NWO grant with €2.2M additional investment from businesses and sports organizations. 4.5 million sports injuries occur annually in the Netherlands costing €5 billion in medical costs.
- AdidasmajorPartner in NWO Perspectief PLatform program to develop sensors for sports injury prevention. Adidas provides industry expertise and co-investment of €2.2M alongside other partners including TUDelft and NedCard.
- GentagcoreJoined forces with Gentag, Mayo Clinic, and Fraunhofer in 2015 for joint development of sensor technologies. Gentag brings expertise in wearable sensor technology and NFC communication.
- Mayo CliniccorePartnered with NovioSense, Gentag, and Fraunhofer for joint sensor technology development. Mayo Clinic provides clinical expertise and research capabilities for validation of sensor technologies.
- BioGEL ETN (Horizon 2020)majorBioGEL European Training Network funded €3M to educate 14 young scientists developing innovative hydrogel chemistries for biomedical applications. NovioSense participates in developing functional and responsive hydrogels for medical device coatings.
- Fraunhofer IMScoreCo-developed application-specific integrated circuits (ASICs) with Fraunhofer IMS. The ASIC technology developed pushes the boundaries of power consumption and sensitivity for wearable sensors. This partnership is fundamental to the device's wireless measurement capabilities.
- Radboud UniversitycoreResearch partner in iTERM Marie Curie Program and InterReg IV A project. Dr. Daniela Wilson serves as assistant professor at Radboud University contributing expertise in bio-organic chemistry.
- NedCardmajorPartner in NWO Perspectief PLatform program with TUDelft and Adidas for sports injury prevention sensor development.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
NOVIOSENSE competitors and assessment
Company assessmentBroad incumbents
- LifeScan: OneTouch BGM brand now owned by Platinum Equity; competes in the broader glucose self-monitoring market that NovioSense intends to disrupt.
- Ascensia Diabetes Care: Specialty diabetes care company (Contour BGM portfolio) and an obvious strategic acquirer or partner for any non-invasive glucose monitoring entrant.
- Medtronic Diabetes: Operates a broad diabetes franchise including insulin pumps, Guardian CGM, and closed-loop systems. Overlaps with NovioSense in CGM and potential closed-loop integration with insulin pumps.
- Roche Diabetes Care: Major diabetes care incumbent offering Accu-Chek BGM systems and increasingly digital/monitoring solutions. Comparable as a large player operating in the glucose self-monitoring category NovioSense targets.
Direct peers
- Senseonics Holdings: Developer of Eversense, the only long-term implantable CGM. Closely comparable as a smaller player pursuing an alternative glucose-sensing modality and clinical-validation pathway.
- Dexcom: Market-leading continuous glucose monitor (GCM) manufacturer whose interstitial-fluid CGM systems (G6, G7) are the primary incumbent NovioSense would compete with in non-invasive glucose monitoring.
- Abbott Diabetes Care: Maker of FreeStyle Libre, the dominant factory-calibrated flash glucose monitor. Direct overlap with NovioSense in the continuous glucose monitoring category for diabetic patients.
Emerging players
- Cnoga Medical: Israeli developer of non-invasive glucose monitoring devices using optical signal processing. Comparable emerging peer in the non-invasive glucose monitoring space.
- Integrity Applications: Developer of GlucoTrack, a non-invasive ear-clip glucose monitor. Direct emerging peer pursuing the same non-invasive CGM opportunity NovioSense targets.
Others
- Mediq: European diabetes care distributor and NovioSense supervisory board member via Marco Verhofstadt. Direct channel/distribution partner and natural route to EU commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NOVIOSENSE social profiles
Digital presenceNOVIOSENSE financial estimates
Financial estimateRevenue estimate
Valuation estimate
NOVIOSENSE leadership team
Management profileNumber of profiles
Profiles5 records
NOVIOSENSE funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NOVIOSENSE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NOVIOSENSE
What does NOVIOSENSE do?
NovioSense develops a non-invasive tear glucose sensor: a small flexible spring-like device (less than 2 cm long, 1.5 mm diameter) coated with soft hydrogel that sits in the lower eyelid to continuously measure glucose levels in tear fluid. The device uses glucose-oxidase enzymatic detection and wireless NFC communication to enable pain-free glucose monitoring for Type 1 and Type 2 diabetic patients, transmitting readings to NFC-enabled smartphones or a dedicated reader system.
Is NOVIOSENSE a public or private company?
NOVIOSENSE is a private company. It is classified as venture growth investor backed and is currently operating.
When was NOVIOSENSE founded?
NOVIOSENSE was founded in 2012. It employs 1 to 10 people.
Where is NOVIOSENSE based?
NOVIOSENSE is headquartered in Nijmegen, Netherlands, in the Europe region.
How does NOVIOSENSE make money?
One revenue line is on record: tear Glucose Sensor Device Sales.
Who are NOVIOSENSE's main competitors?
Broad incumbents on record are LifeScan, Ascensia Diabetes Care, Medtronic Diabetes and Roche Diabetes Care. Direct peers are Senseonics Holdings, Dexcom and Abbott Diabetes Care. Emerging players are Cnoga Medical and Integrity Applications. Mediq is listed as an others.
Does NOVIOSENSE have an API?
No public API is recorded for NOVIOSENSE.
What industry is NOVIOSENSE in?
NOVIOSENSE's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers). Its NAICS code is 334510 and its SIC code is 3841.